Background {#Sec1}
==========

An ongoing outbreak of coronavirus disease 2019 (COVID-19) is spreading globally \[[@CR1], [@CR2]\]. As of April 29, 2020, the number of total confirmed cases has exceeded 3 million, associated to 207,973 deaths worldwide \[[@CR1]\]. Recently, several articles \[[@CR3]--[@CR5]\] have reported that the early acute respiratory distress syndrome (ARDS) caused by coronavirus disease 2019 (COVID-19) significantly differ from those of ARDS due to other causes, such as mismatch between changes in respiratory mechanics and severity of impaired oxygenation \[[@CR3]\], significantly decreased ventilation efficiency \[[@CR4]\], and lower lung recruitability \[[@CR5]\]. We also found that many mechanically ventilated COVID-19 patients recovering from severe ARDS experienced gradual increases in CO~2~ retention and minute ventilation (MV). To explain these pathophysiological features and discuss the ventilatory strategy during the late phase of severe ARDS in COVID-19 patients, we first used a metabolic module (COVX module; GE Healthcare, Helsinki, Finland) on a General Electric R860 ventilator (Engstrom Carestation; GE Healthcare, USA) to monitor parameters related to gas metabolism, end-expiratory lung volume (EELV), physiological dead space, ventilatory ratio (VR) \[[@CR4]\], and lung mechanics in two COVID-19 patients.

Case presentation {#Sec2}
=================

Case 1: A 70-year-old woman (BMI, 21.5 kg/m^2^) with acute respiratory failure caused by COVID-19 was transferred to Tongji Hospital (Wuhan, China) on February 26, 2020. On admission, she had severe dyspnea (respiratory rate \[RR\], 40 bpm) and acute hypoxemic respiratory failure (oxygen saturation 45% with oxygen flow 12 L/min) and underwent endotracheal intubation immediately. A tracheotomy was performed 6 days post-admission. She was supported in pressure control mode: inspiratory pressure 15--18 cmH~2~O and positive end-expiratory pressure (PEEP) 6--8 cmH~2~O. About 14 days post-admission, she experienced a gradual increase in RR (from 25 to 30--40 bpm), tidal volume (VT, from 410 to 480 ml \[7.6--9.1 ml/kg PBW\]), and MV (from 10 to 12--15 L/min), accompanied by an increased PaCO~2~ (from 39 to 47--60 mmHg) and decreased oxygenation (arterial partial pressure of oxygen \[PaO2\]/fraction of inspired oxygen \[FiO2\], from 127 to 74--100 mmHg; FiO~2~, from 0.5 to 0.7). On day 15, the ventilator was changed to an R860 ventilator with COVX module. The following data were recorded: oxygen consumption (VO~2~) 280 ml/min, CO~2~ elimination (VCO~2~) 175 ml/min; ratio of dead space to VT (VD/VT) 78%, end-tidal carbon dioxide (ETCO~2~) 26.1 mmHg, arterial to end-tidal CO~2~ difference (P~(a-ET)~CO~2~) 22.3 mmHg, VR 3.57; EELV 1672 ml; airway resistance (R) 10.8 cmH~2~O/L/s, and respiratory system compliance (Cresp) 12.5 ml/cmH~2~O. Chest computed tomography (CT) revealed bilateral diffuse ground glass opacity, interstitial fibrosis, traction bronchiectasis, and a small amount of consolidation in the dependent aspects of the lungs on 2 day and 19 day after admission (Fig. [1](#Fig1){ref-type="fig"}). Forty days after admission, her lung function still did not recover from sustained hypercapnia in the treatment of Lopinavir/ritonavir, infusion of convalescent plasma, low molecular weight heparin and prone position ventilation, and was transferred to another hospital. Fig. 1Left: transverse chest CT images from a 70-year-old female COVID-19 patient showing bilateral diffuse ground glass opacity, interstitial fibrosis, traction bronchiectasis and a small amount of lung consolidation in the dependent lungs on 2 and 19 days after invasive ventilation. Right: transverse chest CT images from a 42-year-old male COVID-19 patient showing bilateral ground glass opacity, interstitial fibrosis, left pleural effusion and traction bronchiectasis on 36 days and 48 days after invasive ventilation

Case 2: A 42-year-old man (BMI, 22.9 kg/m^2^) diagnosed with COVID-19 was transferred to Tongji Hospital (Wuhan, China) on March 3, 2020. Tracheal intubation and venous-venous extracorporeal membrane oxygenation (ECMO) were performed 25 and 24 days, respectively, before admission due to severe refractory ARDS. ECMO catheters were removed after 14 days of treatment due to a severe blood stream infection. However, ECMO was performed again due to bilateral pneumothorax 8 days before admission. Post-admission, he was treated with antiviral therapy, antibiotic therapy, tracheotomy (1 day post-admission), prone ventilation, and other treatments using our standard protocol. Oxygenation improved gradually, and the ECMO catheter was removed again 19 days post-admission. Over the next week, he showed a gradual increase in MV and hypercapnia. On day 26 post-admission, he was ventilated mechanically in pressure support mode: pressure support 18 cmH~2~O, PEEP 3 cmH~2~O, FiO~2~ 0.3, VT 651 ml (9.2 ml/kg), RR 31 bpm, and MV 17.9 L/min. Arterial blood gas revealed the following: pH 7.463, PaCO~2~ 51 mmHg, PaO~2~ 80.4 mmHg, HCO~3~ 34.9 mmol/L, and PaO2/FiO2 268 mmHg. The following data were recorded using the COVX module: VO~2~ 401 ml/min, VCO~2~ 292 ml/min; VD/VT 76%, ETCO~2~ 33.2 mmHg, P~(a-ET)~CO~2~ 17.8 mmHg, VR 3.4; EELV 1000 ml; R 7.7 cmH~2~O/L/s and Cresp 19.6 ml/cmH~2~O. Chest CT showed bilateral ground glass opacity, interstitial fibrosis, and traction bronchiectasis 11 days and 23 days post-admission (Fig. [1](#Fig1){ref-type="fig"}). He was disconnected from invasive ventilator and transferred to another hospital for further pulmonary rehabilitation on 38 days post-admission.

Discussion and conclusion {#Sec3}
=========================

We found that the lung tissue of COVID-19 patients recovering from severe ARDS not only reflects the typical characteristics of late-phase ARDS (reduced lung compliance, pulmonary fibrosis, and decreased EELV) but is also associated with a significantly increased dead space (VD/VT 70--80%, VR 3--4), markedly higher than that in patients with severe ARDS due to other reasons \[[@CR6]\]. Besides, some COVID-19 patients show an obvious hypermetabolic status even in the recovery period. Therefore, significantly decreased ventilation efficiency and hypermetabolism may explain why these patients experienced more severe respiratory distress and CO~2~ retention in the late phase of ARDS.

A remarkably increased physiological dead space may be a prominent pathophysiological feature in mechanically ventilated COVID-19 patients recovering from severe ARDS; however, the underlying mechanism remains unclear. It may be related to significant regional ventilation/perfusion heterogeneity \[[@CR7]\] due to loss of lung perfusion regulation and hypoxic vasoconstriction \[[@CR3]\], pulmonary microthrombosis \[[@CR8]\], and increased anatomical dead space from obvious traction bronchiectasis observed on chest CT.

To reduce the risk of ventilator-induced lung injury with high tidal volume (8--9 ml/kg), we tried to reduce the VT (6--8 ml/kg) and increase the RR to maintain the MV. However, severe hypercapnia (PaCO~2~ 98 mmHg, pH 7.10 in case 2) was observed, and the use of sedatives and anesthetic agents had to be increased. These serious consequences are worthy of attention. In these two patients, we set a higher VT (8--9 ml/kg), lower peak airway pressure (\< 25 cmH~2~O), and low PEEP levels (3--6 cmH~2~O) due to low lung recruitability; barotrauma did not occur. Of course, our experience from few patients cannot be extrapolated to all COVID-19 patients, however, this report provides a possible more suitable lung protective ventilation for COVID-19 patients recovering from acute respiratory failure with refractory hypercapnia, which deserved to be further investigated in clinical research.

In conclusion, during the recovery period of ARDS in mechanically ventilated COVID-19 patients, attention should be paid to the monitoring of physiological dead space and VR \[[@CR4]\]. Tidal volume (8--9 ml/kg) could be increased appropriately under the limited plateau pressure; however, barotrauma should still be considered. In theory, extracorporeal CO~2~ removal is a better choice for these patients \[[@CR9]\] and will be more beneficial to reduce lung injury while awaiting lung tissue repair; however, further clinical investigations are warranted.
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